Analyst Ratings For ImmunoGen (NASDAQ:IMGN)
Today, Royal Bank of Canada reiterated its Outperform rating on ImmunoGen (NASDAQ:IMGN) with a price target of $12.00.
Some recent analyst ratings include
- 2/8/2018-Royal Bank of Canada Reiterated Rating of Outperform .
- 1/31/2018-HC Wainwright initiated coverage with a Buy rating.
- 11/3/2017-Cantor Fitzgerald Reiterated Rating of Hold.
- 10/12/2017-Jefferies Group Reiterated Rating of Buy.
- 8/30/2017-Canaccord Genuity Reiterated Rating of Buy.
- 8/29/2017-Cowen Reiterated Rating of Hold.
- 8/29/2017-Leerink Swann Reiterated Rating of Outperform .
Recent Insider Trading Activity For ImmunoGen (NASDAQ:IMGN)
ImmunoGen (NASDAQ:IMGN) has insider ownership of 6.51% and institutional ownership of 67.88%.
- On 1/8/2018 Richard J Gregory, VP, sold 2,904 with an average share price of $6.64 per share and the total transaction amounting to $19,282.56.
- On 9/15/2017 Craig Barrows, VP, sold 37,050 with an average share price of $6.81 per share and the total transaction amounting to $252,310.50.
- On 9/13/2017 Craig Barrows, VP, sold 14,600 with an average share price of $6.95 per share and the total transaction amounting to $101,470.00.
- On 12/15/2016 Mark Alan Goldberg, Director, bought 20,000 with an average share price of $1.80 per share and the total transaction amounting to $36,000.00.
- On 11/8/2016 Mark J Enyedy, CEO, bought 25,000 with an average share price of $1.83 per share and the total transaction amounting to $45,750.00.
- On 11/2/2016 Craig Barrows, Insider, bought 10,000 with an average share price of $1.71 per share and the total transaction amounting to $17,100.00.
- On 11/2/2016 Richard J Gregory, VP, bought 16,600 with an average share price of $1.78 per share and the total transaction amounting to $29,548.00.
Recent Trading Activity for ImmunoGen (NASDAQ:IMGN)
Shares of ImmunoGen closed the previous trading session at 8.80 down -0.21 2.33% with 9.170000076293945 shares trading hands.